Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.3552W HIGH $26.25
Volume
1.76 M
Value Traded
102.77 M
Short % Float
8.94%
+0.18%Week
-7.01%1 Month
-22.36%3 Month
+52.45%6 Month
-58.9%5 Year
-16.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.60 B
EPS (TTM)
-2.63
P/E Ratio
-
Ent. Value
3.55 B
Total Shares
134.37 M
Float Shares
126.90 M
Insiders
5.56%
Institutions
84.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DFTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Definium Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Definium Therapeutics, Inc.
275Total events
2Upcoming
69Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Grant / FundingCorporate
Inducement stock options granted to two new non-executive employees
●Corporate ApprovalCorporate
Compensation Committee approved inducement grants under Nasdaq Rule 5635(c)(4)
▼Equity OfferingCorporate
Inducement stock options granted to 15 new employees (334,810 shares)
●Corporate ApprovalCorporate
Compensation Committee approved inducement grants under Nasdaq Rule 5635(c)(4)
▲Topline ReadoutDT120Clinical Data
Positive topline results from Phase 3 Panorama study of DT120 ODT in GAD
generalized anxiety disordersource ↗
▲Breakthrough Therapy DesignationDT120Designation
FDA grants Breakthrough Therapy designation to DT120 ODT for MDD
Major Depressive Disorder (MDD)source ↗
▲Primary Endpoint MetDT120Clinical Data
Phase 3 Emerge study met primary endpoint with statistically significant MADRS improvement
major depressive disordersource ↗
▲Primary Endpoint MetDT120Clinical Data
Voyage met primary endpoint with statistically significant HAM-A improvement
generalized anxiety disordersource ↗
●Oral PresentationDT120Presentation
Webcast to review Phase 3 Voyage topline results
generalized anxiety disordersource ↗
▲Topline ReadoutDT120Clinical Data
Positive topline results from Phase 3 Voyage study of DT120 ODT in GAD
generalized anxiety disordersource ↗
●Quarterly UpdateCorporate
Definium Therapeutics to report Q2 2026 financial results and discuss business highlights
◆Topline ReadoutDT120Clinical Data
Topline data from Panorama Phase 3 study of DT120 ODT in GAD
generalized anxiety disorder (GAD)source ↗
◆Topline ReadoutMM120Clinical Data
MM120-310 for MDD Phase 3 Readout
Major Depressive Disordersource ↗
▼Equity OfferingCorporate
Closing of $805 million upsized public offering including full exercise of underwriters' option
▲Topline ReadoutDT120Clinical Data
Positive topline results from Phase 3 Emerge study of DT120 ODT in Major Depressive Disorder
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study
Major Depressive Disordersource ↗
◆R&D DayPresentation
Definium Therapeutics to participate in 2026 Jefferies Global Healthcare Conference
◆Topline ReadoutDT120Clinical Data
Topline data from Emerge Phase 3 study of DT120 ODT in MDD
major depressive disorder (MDD)source ↗
◆Trial InitiationDT120Trial
Initiation of Ascend Phase 3 study of DT120 ODT in MDD
major depressive disorder (MDD)source ↗
◆Topline ReadoutMM120Clinical Data
Topline data from Phase 3 Emerge study (Part A) in MDD
Major Depressive Disorder (MDD)source ↗
●Trial InitiationMM120Trial
Initiation of Phase 3 Ascend study in MDD
Major Depressive Disorder (MDD)source ↗
▲First Patient DosedDT120Trial
First patient dosed in Ascend Phase 3 study of DT120 ODT in MDD
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
Needham Virtual Psychedelics Forum Panel: Clinical Risk, Regulatory Reality and the Path to Scale
◆Oral PresentationPresentation
25th Annual Needham Virtual Healthcare Conference Fireside Chat
◆Topline ReadoutMM120Clinical Data
Topline data from 12-week double-blind period of Panorama study
generalized anxiety disordersource ↗
◆Topline ReadoutDT120Clinical Data
Topline data from Voyage Phase 3 study of DT120 ODT in GAD
generalized anxiety disorder (GAD)source ↗
◆Oral PresentationPresentation
Analyst Day highlighting pivotal programs, pipeline and path to commercialization
▲First Patient DosedDT120Trial
First patient dosing for Ascend Phase 3 MDD trial
major depressive disordersource ↗
◆Trial InitiationMM120Trial
MM120-311 Phase 3 study initiation in MDD
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
Definium Therapeutics management to present at Oppenheimer 36th Annual Healthcare Conference
◆Oral PresentationPresentation
Definium Therapeutics management to present at TD Cowen 46th Annual Health Care Conference
▲Enrollment CompleteDT120Trial
Voyage Phase 3 GAD trial enrollment expected to complete in coming weeks
generalized anxiety disordersource ↗
▲Enrollment CompleteDT120Trial
Emerge Phase 3 MDD trial enrollment completed
major depressive disordersource ↗
▲Enrollment UpdateDT120Trial
Voyage Phase 3 GAD trial approximately 80% enrolled
generalized anxiety disordersource ↗
▲Full ResultsDT120Clinical Data
Full study results published in JAMA from Phase 2b trial of DT120 in GAD
generalized anxiety disordersource ↗
▲Breakthrough Therapy DesignationDT120Designation
FDA Breakthrough Designation for DT120 in GAD
generalized anxiety disordersource ↗
●Quarterly UpdateCorporate
Full-year 2025 financial results and business updates conference call
◆Oral PresentationPresentation
Presenting at the 44th Annual J.P. Morgan Healthcare Conference
◆Topline ReadoutMM120Clinical Data
Topline data from Phase 3 Voyage trial Part A anticipated in first half of 2026
Generalized Anxiety Disorder (GAD)source ↗
◆Topline ReadoutMM120Clinical Data
MM120-301 for GAD Phase 3 Readout
Generalized Anxiety Disordersource ↗
▲Management ChangeCorporate
Appointment of Roger Adsett to Board of Directors in January 2026
Past FDA Catalysts and PDUFA Decisions
How DFTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-17 | DT120 (lysergide) | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 12%
Small Cap(rank 80 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT120 Small moleculeNCT06941844 | Major Depressive Disorder | Phase 3 | ACTIVE NOT_RECRUITING | 314 | Feb 1, 2027 | ||||||
| DT120 Small moleculeNCT06809595 | Generalized Anxiety Disorder | Phase 3 | ACTIVE NOT_RECRUITING | 459 | May 1, 2027 | ||||||
| DT402 Small moleculeNCT07303907 | Autism Spectrum Disorder | Phase 2 | RECRUITING | 20 | Aug 1, 2027 | ||||||
| MM120 Small moleculeCompletedNCT05407064 | Anxiety Generalized | Phase 2 | COMPLETED | 198 | Nov 27, 2023 | ||||||
| MM120 Small moleculeCompletedNCT05200936 | ADHD | Phase 2 | COMPLETED | 53 | Dec 4, 2023 | ||||||
| 18-MC Compound Small moleculeCompletedNCT04292197 | Addiction | Phase 1 | COMPLETED | 108 | Dec 31, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every DFTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Roberts BrandiOfficer (Chief Financial Officer) | Sell | -3,377 394,528 held | $36.57 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DFTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 3 % (233.3 %) | 338.17 M | 7.19 M | 43.78% ( 2.19 M) |
DFTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DFTX ranks across every disease it competes in
Competitive Position is a premium feature
See how DFTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDFTX News
DFTX▼ -0.4%today
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics has announced the issuance of inducement grants to two new non-executive employees, totaling 45,940 options to purchase common shares. These options will vest over four years, starting with 25% after the first year. This move is part of Definium's strategy to attract talent as it develops new therapeutics for psychiatric and neurological disorders.
Read more →DFTXDefinium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder (GAD). The study met its primary endpoint, showing a significant reduction in anxiety scores compared to placebo. DT120 ODT was well tolerated, and the company plans to submit a New Drug Application (NDA) in 2027.
Read more →DFTXDefinium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Definium Therapeutics will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study evaluating DT120 ODT in adults with generalized anxiety disorder. The study involved 245 participants and assessed the efficacy and safety of the treatment over a 56-week period. The primary endpoint focuses on changes in anxiety scores after 12 weeks of treatment.
Read more →DFTXDefinium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Definium Therapeutics announced it will present topline data from its Phase 3 Emerge and Voyage trials at the Psych Congress 2026. The event, scheduled for September 15-19 in New Orleans, LA, will feature six poster presentations highlighting findings from their DT120 Orally Disintegrating Tablet. This presentation aims to address major depressive disorder and generalized anxiety disorder.
Read more →DFTXDefinium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
Definium Therapeutics has received Breakthrough Therapy designation from the FDA for its DT120 (lysergide) orally disintegrating tablet, aimed at treating Major Depressive Disorder (MDD). This designation highlights the significant unmet medical need in the MDD space. The decision is supported by positive results from Phase 3 clinical trials.
Read more →DFTXDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, a late-stage clinical biopharmaceutical company, announced its participation in upcoming investor conferences and events. The management team will engage in discussions to highlight their innovative therapeutics aimed at psychiatric and neurological disorders. This initiative reflects the company's commitment to investor relations and transparency.
Read more →DFTXDefinium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120, an orally disintegrating tablet for treating generalized anxiety disorder. This marks a significant milestone for the company as it seeks to address psychiatric and neurological disorders. The results suggest DT120's potential effectiveness in adults suffering from GAD.
Read more →DFTXDefinium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Definium Therapeutics reported its financial results for Q2 2026, highlighting significant progress in its development of therapeutics for psychiatric and neurological disorders. The company emphasized its leadership position in the psychedelics sector, marking the quarter as a pivotal moment in its growth. Recent achievements further underscore its commitment to addressing critical health issues.
Read more →DFTXDefinium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Definium Therapeutics, a late-stage clinical biopharmaceutical company, will report its second quarter financial results for 2026 on August 6, 2026. The company aims to address psychiatric and neurological disorders with its therapeutics. A webcast will be held at 4:30 p.m. EDT to discuss these results and recent business highlights.
Read more →DFTXDefinium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Definium Therapeutics has launched 'Wired for Worry', an initiative aimed at educating healthcare providers about generalized anxiety disorder (GAD). This program seeks to enhance understanding of GAD's impact and neurobiology, addressing a significant gap in psychiatric care. The initiative reflects Definium's commitment to improving treatment approaches for psychiatric disorders.
Read more →DFTX▲ +5.3%on this newsshared move
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
Definium Therapeutics has published a healthcare claims study revealing significant treatment patterns among patients with Generalized Anxiety Disorder (GAD). The study highlights high rates of treatment switching and discontinuation, which may indicate challenges in managing the condition. This research aims to inform better therapeutic strategies for GAD patients.
Read more →DFTXDefinium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Definium Therapeutics, Inc. has successfully closed an upsized public offering totaling $805 million. This offering included the full exercise of the underwriters' option to purchase additional shares, reflecting strong investor interest and confidence in the company's future prospects. The funds raised will likely support Definium's ongoing projects and initiatives.
Read more →DFTX▲ +16.4%on this news· ran to +29% by day 3shared move
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. has announced the pricing of its upsized public offering, raising $700 million. This move indicates the company's efforts to strengthen its financial position. Further details regarding the offering's use of proceeds and investor interest were not disclosed in the announcement.
Read more →About Definium Therapeutics, Inc.
HeadquartersONE WORLD TRADE CENTER, NEW YORK, NY, 10007
BIOPHARMAWATCH ELITE PLUS
Trade the next DFTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime